报价延迟最少15分钟:2026/06/02 10:17 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.3993 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
--/--
|
|
企业价值
20.58M
|
| 资产负债 |
|
每股账面净值
3.83
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.18M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements. |
